Efficacy and safety of sitagliptin in elderly patients with type 2 diabetes mellitus.

Motoko TagoJun-Ichi OyamaYoshiko SakamotoAya ShirakiFumi UchidaAtsuko ChiharaHideo IkedaShigetaka KurokiShigeki GondoTaketo IwamotoYasufumi UchidaKoichi Node

Published in: Geriatrics & gerontology international (2018)

Sitagliptin treatment offers elderly patients aged ≥65 years efficacious and safe reductions in HbA1c values regardless of BMI. Geriatr Gerontol Int 2018; 18: 631-639.

Keyphrases

body mass index
weight gain
smoking cessation